Pfizer (NYSE:PFE) is preparing multiple presentations for the upcoming ASCO conference that spotlight new data across its ...

Pfizer's vaccine business cooled off, and it is on its back foot in the GLP-1 race, but don't count the drug giant out.

Pfizer (NYSE:PFE) received U.S. FDA Priority Review for a supplemental Biologics License Application covering PADCEV plus ...

Pfizer continues delivering consistent earnings beats, driven by cost-cutting initiatives and improving margins. Learn more ...

Track Pfizer share price today on NSE/BSE with real-time updates. Check stock performance, fundamentals, market cap, shareholding, financial reports, annual & quarterly results, and profit & loss ...

Pfizer’s monthly GLP-one obesity candidate and broad clinical program add fresh attention to its healthcare pipeline and long ...

Pfizer reported fourth-quarter revenue and earnings that topped estimates even amid dwindling demand for its Covid products. The pharmaceutical giant reaffirmed the modest 2026 outlook that rattled ...

During Pfizer's right-sizing push after the COVID-19 pandemic, the company's multibillion-dollar cost-cutting campaign has ...

--Currently down nine consecutive days; down 11.06% over this period --Longest losing streak since Feb. 25, 2020, when it fell for nine straight trading days --Worst nine-day stretch since the nine ...

Pfizer is facing a patent cliff and has a high payout ratio, but it is taking steps to get back on track. That kind of price decline doesn't happen by accident, which means you need to carefully ...